000079367 001__ 79367
000079367 005__ 20200117221618.0
000079367 0247_ $$2doi$$a10.1007/s13105-018-0638-9
000079367 0248_ $$2sideral$$a109475
000079367 037__ $$aART-2018-109475
000079367 041__ $$aeng
000079367 100__ $$aPerez-Diaz, S.
000079367 245__ $$aPTRF acts as an adipokine contributing to adipocyte dysfunctionality and ectopic lipid deposition
000079367 260__ $$c2018
000079367 5060_ $$aAccess copy available to the general public$$fUnrestricted
000079367 5203_ $$aAdipose tissue (AT) expands under obesogenic conditions. Yet, when the growth exceeds a certain limit, AT becomes dysfunctional and surplus lipids start depositing ectopically. Polymerase I and transcription release factor (PTRF) has been proposed as a mechanism leading to a dysfunctional AT by decreasing the adipogenic potential of human adipocyte precursors. However, whether or not PTRF can be secreted by the adipocytes into the bloodstream is not yet known. For this work, PTRF presence was investigated in plasma. We also produced a recombinant PTRF (rPTRF) and examined its impact on the functional interactions between the adipocyte and the hepatocyte in vitro. We demonstrated that PTRF can be found in human plasma, and is at least in part, carried by exosomes. In vitro treatment with rPTRF increased the hypertrophy and senescence of 3T3-L1 adipocytes. In turn, those rPTRF-treated adipocytes increased lipid accumulation in hepatocytes. Lastly, we found a positive correlation between circulating PTRF and the concentration of PTRF in the visceral fat depot. All these findings point toward the presence of an enlarged and dysfunctional visceral adipose tissue which secretes PTRF. This circulating PTRF behaves as an adipokine and may partially contribute to the well-known detrimental effects of visceral fat accumulation.
000079367 536__ $$9info:eu-repo/grantAgreement/ES/FEDER/Una manera de hacer Europa
000079367 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000079367 590__ $$a2.523$$b2018
000079367 591__ $$aPHYSIOLOGY$$b38 / 81 = 0.469$$c2018$$dQ2$$eT2
000079367 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b169 / 294 = 0.575$$c2018$$dQ3$$eT2
000079367 592__ $$a0.872$$b2018
000079367 593__ $$aBiochemistry$$c2018$$dQ2
000079367 593__ $$aPhysiology$$c2018$$dQ2
000079367 593__ $$aMedicine (miscellaneous)$$c2018$$dQ2
000079367 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000079367 700__ $$aGarcia-Sobreviela, M.P.
000079367 700__ $$aGonzalez-Irazabal, Y.
000079367 700__ $$aGarcia-Rodriguez, B.
000079367 700__ $$aEspina, S.
000079367 700__ $$aArenaz, I.
000079367 700__ $$aArbones-Mainar, J.M.
000079367 773__ $$g74, 4 (2018), 613-622$$pJ. physiol. biochem.$$tJournal of Physiology and Biochemistry$$x1138-7548
000079367 8564_ $$s769291$$uhttps://zaguan.unizar.es/record/79367/files/texto_completo.pdf$$yPostprint
000079367 8564_ $$s10597$$uhttps://zaguan.unizar.es/record/79367/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000079367 909CO $$ooai:zaguan.unizar.es:79367$$particulos$$pdriver
000079367 951__ $$a2020-01-17-21:52:18
000079367 980__ $$aARTICLE